• Evaxion Biotech A/S EVAX.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-8.00. The mean expectation of two analysts for the quarter was for a loss of $3.88 per share.

• Revenue was $122.00 thousand​; analysts expected $1.66 million.

• Evaxion Biotech A/S's reported EPS for the quarter was a loss of 7 cents​.

• The company reported a quarterly loss of $3.63 million.

• Evaxion Biotech A/S shares had held steady so far this quarter and lost 56.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 106.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Evaxion Biotech A/S is $44.88

This summary was machine generated from LSEG data April 1 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)